Statin use and risk of diabetes mellitus

World Journal of Diabetes
Bharti ChogtuK L Bairy

Abstract

The 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors, statins, are widely used in the primary and secondary prevention of cardiovascular diseases to lower serum cholesterol levels. As type 2 diabetes mellitus is accompanied by dyslipidemia, statins have a major role in preventing the long term complications in diabetes and are recommended for diabetics with normal low density lipoprotein levels as well. In 2012, United States Food and Drug Administration released changes to statin safety label to include that statins have been found to increase glycosylated haemoglobin and fasting serum glucose levels. Many studies done on patients with cardiovascular risk factors have shown that statins have diabetogenic potential and the effect varies as per the dosage and type used. The various mechanisms for this effect have been proposed and one of them is downregulation of glucose transporters by the statins. The recommendations by the investigators are that though statins can have diabetogenic risk, they have more long term benefits which can outweigh the risk. In elderly patients and those with metabolic syndrome, as the risk of diabetes increase, the statins should be used cautiously. Other than a subset of population with risk...Continue Reading

Citations

Oct 6, 2015·Expert Opinion on Drug Safety·Aris P AgouridisMoses S Elisaf
Apr 9, 2016·Wiener klinische Wochenschrift·Greisa VilaAnton Luger
Dec 1, 2015·Pulmonary Medicine·Dipanjan BhattacharjeeRahul Magazine
Oct 21, 2016·Expert Opinion on Therapeutic Patents·Eduardo Filipe OliveiraPedro Alexandrino Fernandes
Jul 14, 2016·Evidence-based Medicine·Fares AlahdabM Hassan Murad
Jul 8, 2017·Expert Opinion on Pharmacotherapy·Niki KatsikiDimitri P Mikhailidis
Feb 13, 2018·Expert Review of Clinical Pharmacology·Konstantinos StavropoulosVasilios G Athyros
Dec 21, 2017·Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences·Aleksandra KlisicAna Ninic
Mar 3, 2020·Immunopharmacology and Immunotoxicology·Souty M Z SharkawiRamadan A M Hemeida
Nov 22, 2016·Lipid Insights·Jonathan T DaviesHollie I Swanson
Jun 4, 2019·Journal of Biomaterials Science. Polymer Edition·Gizem UzunoğluAdil Denizli
Mar 29, 2019·Journal of Diabetes and Metabolic Disorders·Sarah CuschieriJulian Mamo
May 1, 2018·Pharmacogenomics·Marc-André LegaultMarie-Pierre Dubé
Nov 5, 2019·Journal of the Neurological Sciences·Johanna Andrea Gutiérrez-Vargas, Gloria Patricia Cardona-Gómez
Jun 19, 2021·Journal of the Endocrine Society·Thaer IdreesAntonio C Bianco

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Journal of Clinical Lipidology
Kevin C Maki The Diabetes Subpanel of the National Lipid Association Expert Panel
Current Atherosclerosis Reports
Kelly AxsomArthur Z Schwartzbard
© 2021 Meta ULC. All rights reserved